Conference
Abstract P3-07-16: Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be?
Abstract
Abstract
Background: The Oncotype DX Recurrence Score (ODX) is commonly used to estimate recurrence risk and chemotherapy benefit in ER positive, node negative breast cancer but is associated with significant cost. The Magee score (MS), a free online calculation using numerical values of commonly assessed pathological features (ER, PR, Her2/neu, and Ki-67), has been validated as an ODX surrogate. This includes the MS using …
Authors
Robertson S; Petkiewicz S; Arnaout A; Clemons M; Gravel D; Pond G
Volume
76
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 15, 2016
DOI
10.1158/1538-7445.sabcs15-p3-07-16
Conference proceedings
Cancer Research
Issue
4_Supplement
ISSN
0008-5472